HemoBioTech Announces Dramatic Clearance of Prions with the ORTH Technology

The ORTH technology was developed at Texas Tech University by Dr. Jan Simoni and his colleagues and HemoBioTech has an exclusive worldwide license to commercialize ORTH. HemoBioTech is pursuing sublicensing the ORTH technology to pharmaceutical and biotechnology companies in return for upfront fees, milestone payments and royalties.

Read the rest of the story at Genetic Engineering News